报价延迟最少15分钟:2025/11/17 04:26 EST
盘前时段
|
||||
|
0.9048 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.9048
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.60/-0.75
|
|
企业价值
94.76M
|
| 资产负债 |
|
每股账面净值
-1.03
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
62.04M
|
|
每股收益
0.67
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/11/17 04:26 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancerand autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others. |
